What is Allos?
Allos operates at the intersection of quantum physics, applied artificial intelligence, and pharmaceutical development. The company utilizes Causal AI to transform existing complex drugs into more bioavailable, safer, and patient-friendly medicines. By reformulating small-molecule drugs and grounding clinical studies in real-world evidence, Allos provides a robust framework for pharmaceutical partners to modernize stalled programs and bring molecules to market with increased speed and precision. This AI-native methodology represents a significant shift in how the industry approaches the lifecycle management of therapeutic assets, moving away from traditional trial-and-error methods toward data-driven, predictive outcomes.
How much funding has Allos raised?
Allos has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2026): $5M with participation from Habico Invest, Oxford Sciences Enterprises, and Berkeley SkyDeck Fund
Key Investors in Allos
Habico Invest
Habico Invest A/S is a Danish family office that specializes in diverse asset class investments, providing strategic capital solutions to foster long-term financial growth.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment firm that partners with the University of Oxford to build and scale transformational businesses in the science and technology sectors.
Berkeley SkyDeck Fund
Berkeley SkyDeck is a premier accelerator affiliated with the University of California, Berkeley, providing early-stage startups with essential mentorship, network access, and venture capital support.
What's next for Allos?
With this latest round of financing, Allos is poised to expand its collaborative efforts with major pharmaceutical entities, focusing on the modernization of legacy portfolios. The strategic roadmap includes scaling the deployment of its Causal AI engine to unlock value in stalled drug programs and enhancing the accessibility of complex generics. As the company matures, the focus will likely shift toward broader clinical validation and the integration of its platform into global drug development workflows. By maintaining its commitment to scientific rigor and AI-driven innovation, Allos is set to redefine the standards for drug bioavailability and safety in the coming years.
See full Allos company page
